Barr Pharmaceuticals’ Duramed subsidiary has signed a product acquisition agreement with Shire for Adderall tablets, as well as a product development agreement for six proprietary products. Also, Barr Laboratories, Inc. has signed a settlement and license agreement relating to two pending patent cases involving Shire’s Adderall XR. The agreements will be submitted to the U.S. Federal Trade Commission as required by law and become effective upon the Courts’ signing of consent ju...